Merck & Co Inc (MRK)

McKesson Corporation "

Major drug wholesaler

All

21% of total accounts receivable as of December 31, 2024 "

Cencora, Inc. "

Major drug wholesaler

All

21% of total accounts receivable as of December 31, 2024 "

Cardinal Health, Inc. "

Major drug wholesaler

All

13% of total accounts receivable as of December 31, 2024 "

MK‑1045 (from Curon Biopharmaceutical)

2024

Merck acquired MK‑1045 for an upfront payment of $700 million as an asset acquisition, with additional contingent milestone payments (up to $300 million each for developmental and regulatory milestones, plus third‑party contingent payments and tiered royalties). The acquisition supports the expansion of its pipeline targeting B‑cell malignancies and autoimmune diseases, with MK‑1045 currently in early‑stage trials. " " " " "

Eyebiotech Limited (EyeBio)

2024

Merck acquired EyeBio for $1.2 billion (plus $207 million in transaction costs) as an asset acquisition that includes potential future contingent payments (up to $200 million, $1.0 billion, and $500 million for various milestones). The acquisition enhances its ophthalmology portfolio, centering on the lead candidate Restoret (MK‑3000), currently in clinical development for diabetic macular edema and neovascular age‑related macular degeneration. " " " "

Elanco Animal Health (Aqua Business)

2024

Merck acquired the aqua business for $1.3 billion in a business combination with no contingent payments, gaining an innovative portfolio including vaccines (e.g., Clynav) and anti‑parasitic treatments (e.g., Imvixa) for aquatic species, along with manufacturing and research facilities in Canada, Vietnam, and Chile. This bolsters its Animal Health portfolio in the aquaculture market. " " " "

Harpoon Therapeutics, Inc.

2024

Merck acquired Harpoon Therapeutics for $765 million (with $56 million in transaction costs) as an asset acquisition, gaining its clinical‑stage lead candidate MK‑6070, a T‑cell engager for SCLC and neuroendocrine tumors, with no future contingent payments. The deal supports Merck's immuno‑oncology strategy, reflected in a recorded R&D charge and net asset recognition. " " " " " "

Prometheus Biosciences, Inc.

2023

Merck acquired Prometheus for approximately $11.0 billion (including cash of $200 per share and share‑based awards) as an asset acquisition that strengthens its immunology capabilities through a precision medicine approach for immune‑mediated diseases, centered on lead candidate MK‑7240. The deal, completed in 2023, involved no future contingent payments and resulted in significant R&D expenses recorded. " " " " " "

Imago BioSciences, Inc.

2023

Merck acquired Imago BioSciences for $1.35 billion (including share‑based equity settlements and $60 million in transaction costs) as an asset acquisition, primarily for its lead candidate bomedemstat (MK‑3543), which is in multiple Phase 2 clinical trials for various hematologic conditions. The acquisition recorded net assets of $219 million and a corresponding R&D charge, with no future contingent payments. " " "

Vence

2022

Merck acquired Vence, a pioneer in virtual fencing for rotational grazing and livestock management, to complement its broad Animal Health portfolio. While financial or operational specifics were not provided, the acquisition strategically enhances Merck's offerings in veterinary solutions. "